Pre-Clinical Pharmacokinetics, Tissue Distribution and Physicochemical Studies of CLBQ14, a Novel Methionine Aminopeptidase Inhibitor for the Treatment of Infectious Diseases

References

• Center for Disease Control and Prevention, Infectious Disease. FastStats: infectious/immune 2017. U.S. Department of Health & Human Services [Updated 119, 2017; cited July 16, 2019].
   Google Scholar
• RocaI, AkovaM, BaqueroF, et al. The global threat of antimicrobial resistance: science for intervention. New Microbes New Infect. 2015;6:22–29. doi:10.1016/j.nmni.2015.02.00726029375
   PubMedGoogle Scholar
• ChaiSC, WangW-L, DingD-R, et al. Growth inhibition of Escherichia coli and methicillin-resistant Staphylococcus aureus by targeting cellular methionine aminopeptidase. Eur J Med Chem. 2011;46(8):3537–3540. doi:10.1016/j.ejmech.2011.04.05621575996
   PubMed Web of Science ®Google Scholar
• OlaleyeO, RaghunandTR, BhatS, et al. Methionine aminopeptidases from Mycobacterium tuberculosis as novel antimycobacterial targets. Chem Biol. 2010;17(1):86–97. doi:10.1016/j.chembiol.2009.12.01420142044
   PubMedGoogle Scholar
• OlaleyeO, RaghunandTR, BhatS, et al. Characterization of clioquinol and analogues as novel inhibitors of methionine aminopeptidases from Mycobacterium tuberculosis. Tuberculosis (Edinb). 2011;91(Suppl 1):S61–5. doi:10.1016/j.tube.2011.10.01222115541
   PubMed Web of Science ®Google Scholar
• JohnSF, AniemekeE, HaNP, et al. Characterization of 2-hydroxy-1-naphthaldehyde isonicotinoyl hydrazone as a novel inhibitor of methionine aminopeptidases from Mycobacterium tuberculosis. Tuberculosis. 2016;101(Supplement):S73–S77. doi:10.1016/j.tube.2016.09.025
   Web of Science ®Google Scholar
• ZhangX, ChenS, HuZ, et al. Expression and characterization of two functional methionine aminopeptidases from Mycobacterium tuberculosis H37Rv. Curr Microbiol. 2009;59(5):520–525. doi:10.1007/s00284-009-9470-319688379
   PubMed Web of Science ®Google Scholar
• KangJ-M, JuH-L, SohnW-M, et al. Characterization of the biochemical properties of two methionine aminopeptidases of Cryptosporidium parvum. Parasitol Int. 2012;61(4):707–710. doi:10.1016/j.parint.2012.05.00822609952
   PubMed Web of Science ®Google Scholar
• ChenX, ChongCR, ShiL, et al. Inhibitors of Plasmodium falciparum methionine aminopeptidase 1b possess antimalarial activity. Proc Natl Acad Sci U S A. 2006;103(39):14548–14553. doi:10.1073/pnas.060410110316983082
   PubMed Web of Science ®Google Scholar
• KumarR, TiwariK, DubeyVK. Methionine aminopeptidase 2 is a key regulator of apoptotic like cell death in Leishmania donovani. Sci Rep. 2017;7(1):95. doi:10.1038/s41598-017-00186-928273904
   PubMed Web of Science ®Google Scholar
• IsicheiA, OlaleyeO. Characterization of CLBQ14 as a Methionine Aminopeptidase Inhibitor in Enterococcus Faecalis. Texas Southern University; 2017 Unpublished manuscript.
   Google Scholar
• KishorC, GumpenaR, ReddiR, et al. Structural studies of Enterococcus faecalis methionine aminopeptidase and design of microbe specific 2, 2ʹ-bipyridine based inhibitors. Med Chem Comm. 2012;3:1406–1412. doi:10.1039/c2md20096a
   Web of Science ®Google Scholar
• HelgrenTR, ChenC, WangtrakuldeeP, et al. Rickettsia prowazekii methionine aminopeptidase as a promising target for the development of antibacterial agents. Bioorg Med Chem. 2017;25(3):813–824. doi:10.1016/j.bmc.2016.11.01328089350
   PubMed Web of Science ®Google Scholar
• YuanH, ChaiSC, LamCK, et al. Two methionine aminopeptidases from Acinetobacter baumannii are functional enzymes. Bioorg Med Chem Lett. 2011;21(11):3395–3398. doi:10.1016/j.bmcl.2011.03.11621524572
   PubMed Web of Science ®Google Scholar
• GriffithEC, SuZ, TurkBE, et al. Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin. Chem Biol. 1997;4(6):461–471. doi:10.1016/S1074-5521(97)90198-89224570
   PubMed Web of Science ®Google Scholar
• EhlersT, FurnessS, Philip RobinsonT, et al. Methionine aminopeptidase Type-2 inhibitors targeting angiogenesis. Curr Top Med Chem. 2016;16(13):1478–1488. doi:10.2174/156802661566615091512120426369821
   PubMed Web of Science ®Google Scholar
• ShimizuH, YamagishiS, ChibaH, et al. Methionine aminopeptidase 2 as a potential therapeutic target for human non-small-cell lung cancers. Adv Clin Exp Med. 2016;25(1):117–128. doi:10.17219/acem/6071526935506
   PubMed Web of Science ®Google Scholar
• ChunE, HanCK, YoonJH, et al. Novel inhibitors targeted to methionine aminopeptidase 2 (MetAP2) strongly inhibit the growth of cancers in xenografted nude model. Int J Cancer. 2005;114(1):124–130. doi:10.1002/(ISSN)1097-021515523682
   PubMed Web of Science ®Google Scholar
• BernierSG, LazarusDD, ClarkE, et al. A methionine aminopeptidase-2 inhibitor, PPI-2458, for the treatment of rheumatoid arthritis. Proc Natl Acad Sci U S A. 2004;101(29):10768–10773. doi:10.1073/pnas.040410510115249666
   PubMed Web of Science ®Google Scholar
• BradshawRA, BrickeyWW, WalkerKW. N-Terminal processing: the methionine aminopeptidase and Nα-acetyl transferase families. Trends Biochem Sci. 1998;23(7):263–267. doi:10.1016/S0968-0004(98)01227-49697417
   PubMed Web of Science ®Google Scholar
• GiglioneC, VallonO, MeinnelT. Control of protein life-span by N-terminal methionine excision. EMBO J. 2003;22(1):13–23. doi:10.1093/emboj/cdg00712505980
   PubMed Web of Science ®Google Scholar
• GiglioneC, BoularotA, MeinnelT. Protein N-terminal methionine excision. Cell Mol Life Sci. 2004;61(12):1455–1474. doi:10.1007/s00018-004-3466-815197470
   PubMed Web of Science ®Google Scholar
• ArfinSM, KendallRL, HallL, et al. Eukaryotic methionyl aminopeptidases: two classes of cobalt-dependent enzymes. Proc Natl Acad Sci U S A. 1995;92(17):7714–7718. doi:10.1073/pnas.92.17.77147644482
   PubMed Web of Science ®Google Scholar
• KeelingPJ, DoolittleWF. Methionine aminopeptidase-1: the MAP of the mitochondrion? Trends Biochem Sci. 1996;21(8):285–286.8772380
   PubMed Web of Science ®Google Scholar
• LowtherWT, MatthewsBW. Structure and function of the methionine aminopeptidases. Biochim Biophys Acta. 2000;1477(1–2):157–167. doi:10.1016/S0167-4838(99)00271-X10708856
   PubMed Web of Science ®Google Scholar
• National Center for Biotechnology Information. PubChem Compound Database; CID=82095. [ cited 3 10, 2017]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/82095. Accessed 318, 2020.
   Google Scholar
• National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals. Guide for the Care and Use of Laboratory Animals. 8th ed. Washington (DC): National Academies Press; 2011.
   Google Scholar
• ChhonkerYS, ChandasanaH, KumarA, et al. Pharmacokinetics, tissue distribution and plasma protein binding studies of rohitukine: a potent anti-hyperlipidemic agent. Drug Res (Stuttg). 2015;65(7):380–387. doi:10.1055/s-0034-138777425243649
   PubMedGoogle Scholar
• EkpenyongO, CooperC, MaJ, et al. A simple, sensitive and reliable LC-MS/MS method for the determination of 7-bromo-5-chloroquinolin-8-ol (CLBQ14), a potent and selective inhibitor of methionine aminopeptidases: application to pharmacokinetic studies. J Chromatogr B Analyt Technol Biomed Life Sci. 2018;1097–1098:35–43. doi:10.1016/j.jchromb.2018.08.027
   PubMed Web of Science ®Google Scholar
• DaviesB, MorrisT. Physiological parameters in laboratory animals and humans. Pharm Res. 1993;10(7):1093–1095. doi:10.1023/A:10189436131228378254
   PubMed Web of Science ®Google Scholar
• TamakiS, KomuraH, KogayuM, et al. Comparative assessment of empirical and physiological approaches on predicting human clearances. J Pharm Sci. 2011;100(3):1147–1155. doi:10.1002/jps.2232120830811
   PubMed Web of Science ®Google Scholar
• YangJ, JameiM, YeoKR, et al. Misuse of the well-stirred model of hepatic drug clearance. Drug Metab Dispos. 2007;35(3):501–502. doi:10.1124/dmd.106.01335917325025
   PubMed Web of Science ®Google Scholar
• WardKW, SmithBR. A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. I. Clearance. Drug Metab Dispos. 2004;32(6):603–611. doi:10.1124/dmd.32.6.60315155551
   PubMed Web of Science ®Google Scholar
• LipinskiCA, LombardoF, DominyBW, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 1997;23(1):3–25. doi:10.1016/S0169-409X(96)00423-1
   Web of Science ®Google Scholar
• BhalSK. LogP—making sense of the value. Advanced Chemistry Development Inc. (ACD/Labs); 2011 Available from: https://www.acdlabs.com/download/app/physchem/making_sense.pdf. Accessed 59, 2019.
   Google Scholar
• O’BrienZ, Fallah MoghaddamM. Small molecule kinase inhibitors approved by the FDA from 2000 to 2011: a systematic review of preclinical ADME data. Expert Opin Drug Metab Toxicol. 2013;12(9):1597–1612. doi:10.1517/17425255.2013.834046
   Web of Science ®Google Scholar
• GadSC, CassidyCD, AubertN, SpainhourB, RobbeH. Nonclinical vehicle use in studies by multiple routes in multiple species. Int J Toxicol. 2006;25(6):499–521. doi:10.1080/1091581060096153117132609
   PubMed Web of Science ®Google Scholar
• ZaretzkiJ, MatlockM, SwamidassSJ. XenoSite: accurately predicting CYP-mediated sites of metabolism with neural networks. J Chem Inf. 2013;53(12):3373–3383.
   Google Scholar
• StewartJJP. MOPAC 2012, Stewart Computational Chemistry. Colorado Springs, CO, USA; 2012.
   Google Scholar
• O’BoyleNM, BanckM, JamesCA, MorleyC, VandermeerschT, HutchisonGR. Open Babel: an open chemical toolbox. J Chem Inf. 2011;3:33. doi:10.1186/1758-2946-3-33
   Google Scholar
• MartignoniM, GroothuisGM, de KanterR. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol. 2006;2(6):875–894. doi:10.1517/17425255.2.6.87517125407
   PubMed Web of Science ®Google Scholar
• SmithDA, JonesBC. Speculations on the substrate structure–activity relationship (SSAR) of cytochrome P450 enzymes. Biochem Pharmacol. 1992;44:2089–2098. doi:10.1016/0006-2952(92)90333-E1472073
   PubMed Web of Science ®Google Scholar
• CreweHK, LennardMS, TuckerGT, et al. The effect of selective serotonin re-uptake inhibitors on cytochrome P450 2D6 (CYP2D6) activity in human liver microsomes. 1992. Br J Clin Pharmacol. 2004;58:S744–S750. doi:10.1111/bcp.2004.58.issue-715595963
   PubMed Web of Science ®Google Scholar
• OsborneDW, MusakhanianJ. Skin penetration and permeation properties of Transcutol®—neat or diluted mixtures. AAPS PharmSciTech. 2018;19(8):3512. doi:10.1208/s12249-018-1196-830421383
   PubMed Web of Science ®Google Scholar